Roche, S-P resolve peginterferon dispute

12 August 2001

Roche and Schering-Plough have entered into a cross-licensing agreementthat they say settles all ongoing patent disputes between the firms regarding their respective peginterferon alfa products, Pegasys (peginterferon alfa 2a) and PegIntron (peginterferon alfa-2b).

As a result of the settlement, each party will license to the other intellectual property relating to the use of peginterferon alfa with the antiviral drug ribavirin. The development allows Roche and S-P to market their products without hindrance, as well as to have them manufactured by third parties. Financial terms were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight